Donostia

• A study to assess efficacy and safety of efgartigimod PH20 SC in adults with ocular myasthenia gravis Ended recruitment
  2024-514133-38-00 5 2025-03-19 Ocular Myasthenia Gravis
• Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson’s Disease (LRRK2-PD) Ended recruitment
  2024-513384-15-00 4 2025-02-13 Parkinson’s disease
• An open label, single-arm, phase 2 study of perioperative sacituzumab govitecan in combination with zimberelimab and domvanalimab for patien … Ended recruitment
  2023-504420-26-00 4 2025-01-13 Bladder Cancer
• Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemother … Ended recruitment
  2024-511957-23-00 5 2025-01-03 Recurrent or Persistent Endometrial Cancer
• Research study on the use of capivasertib together with fulvestrant in patients with advanced breast cancer who have relapsed/progressed to … Ended recruitment
  2024-513952-13-00 5 2025-01-02 HR+ / HER2- advanced breast cancer
• Study to evaluate the use of durvalumab in combination with platinum-based chemotherapy followed by durvalumab with olaparib as first-line t … Ended recruitment
  2024-514728-17-00 11 2024-12-30 Advanced or recurrent endometrial cancer
• Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended recruitment
  2023-504359-29-01 5 2024-12-11 Multiple sclerosis
• A Phase 3 Global Study to Evaluate AOC 1001 for the Treatment of Myotonic Dystrophy Type 1 Ended recruitment
  2024-511378-60-00 5 2024-12-11 Myotonic Dystrophy Type 1
• Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Ended recruitment
  2024-514343-29-00 5 2024-11-19 multiple sclerosis
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants with … Ended recruitment
  2023-508697-28-00 7 2024-11-13 Frontotemporal Dementia (FTD)
• Clinical Trial to compare subcutaneous pembrolizumab given with hyaluronidase to intravenous pembrolizumab in patients with newly diagnosed … Ended recruitment
  2024-513165-39-00 5 2024-11-11 Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS
• A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Ref … Ended recruitment
  2024-516149-38-00 4 2024-10-29 Hodgkin Lymphoma
• A study of safety and tolerability (acceptability of potential side effects) of exidavnemab, at 2 different doses, in patients with Parkinso … Ended recruitment
  2024-511222-30-00 4 2024-10-22 Multiple System Atrophy
• LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Ended recruitment
  2024-512676-36-00 10 2024-10-09 Langerhans Cell Histiocytosis
• A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High- … Ended recruitment
  2023-510178-15-00 5 2024-07-31 High-risk Large B-cell Lymphoma
• Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO712620 … Ended recruitment
  2023-509678-52-00 9 2024-06-27 Alzheimer's disease
• A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei … Ended recruitment
  2023-508306-15-00 5 2024-06-26 Alzheimer’s Disease
• Comparison between rituximab plus zanubrutinib versus rituximab monotherapy in untreated splenic marginal zone lymphoma patients Ended recruitment
  2023-503755-10-00 5 2024-05-17 Splenic marginal zone lymphoma
• Clinical trial to evaluate the safety and efficacy of a 7-day versus 14-day treatment for enterococcal infections. Ended recruitment
  2023-508456-18-00 6 2024-04-29 Uncomplicated bacteremia caused by E. faecalis or E. faecium.
• A trial to learn if taking osimertinib before and after chemotherapy and radiation therapy is safe and works in adults with non-small cell … Ended recruitment
  2023-507798-16-00 4 2024-04-16 Unresectable Non-small Cell Lung Cancer
• Effect of dimethyl fumarate administered to patients with adrenomyeloneuropathy: a multicenter, placebo controlled, phase IIb/III trial Ended recruitment
  2023-506795-27-00 10 2024-04-15 Adrenomyeloneuropathy
• A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheim … Ended recruitment
  2023-506183-13-00 4 2024-03-29 Alzheimer’s Disease
• A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal- … Ended recruitment
  2022-502446-27-00 5 2024-02-26 Relapsed or Refractory Myeloma
• Phase 3 study of perioperative dostarlimab in participants with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancer Ended recruitment
  2023-503265-27-00 5 2023-11-23 Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Co

Showing 97–120 of 200 trials